Lorundrostat

DB18957InvestigationalSmall molecule

Lorundrostat is under investigation in clinical trial NCT06153693 (Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension).

Mechanism: Pharmacologically active on Cytochrome P450 11B2, mitochondrial
Curator reviewed
Formula / weight: C₂₄H₃₃N₇O₂ · 451.575 g/mol (avg)
Also known as: 1-Piperazineacetamide, N-[trans-4-(acetylamino)cyclohexyl]-4-[5-(4-methylphenyl)-1,2,4-triazin-3-yl]- · N-(trans-4-acetamidocyclohexyl)-2-{4-[5-(4-methylphenyl)-1,2,4-triazin-3-yl]piperazin-1-yl}acetamide
Code names: MLS-101 free base · MT-4129 · MT-4129 free base

Resolves to

Compound

UNIIKA8W5LDS6ZCAS1820940-17-7

Structure

InChIKeyYHGVDZULVMINCJ-MEMLXQNLSA-NSMILESCC(=O)N[C@H]1CC[C@@H](CC1)NC(=O)CN1CCN(CC1)C1=NN=CC(=N1)C1=CC=C(C)C=C1

Targets

P19099CYP11B2

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

6Clinical trialsPhase, status and sponsor resolved per trial

8+ReferencesStructured and connected to the statements they support

Which drugs share a target with Lorundrostat, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account